Clinical trials
Completed Ocular Hypertension trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
483 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 5 |
| 2001 | 7 |
| 2002 | 6 |
| 2003 | 13 |
| 2004 | 5 |
| 2005 | 22 |
| 2006 | 23 |
| 2007 | 24 |
| 2008 | 25 |
| 2009 | 34 |
| 2010 | 42 |
| 2011 | 45 |
| 2012 | 23 |
| 2013 | 30 |
| 2014 | 31 |
| 2015 | 15 |
| 2016 | 19 |
| 2017 | 12 |
| 2018 | 18 |
| 2019 | 17 |
| 2020 | 9 |
| 2021 | 13 |
| 2022 | 8 |
| 2023 | 4 |
| 2024 | 8 |
| 2025 | 8 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 483 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Alcon Research | 90 |
| Allergan | 72 |
| Aerie Pharmaceuticals | 22 |
| Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 22 |
| Santen Inc. | 12 |
| Santen Pharmaceutical Co., Ltd. | 12 |
| Mati Therapeutics Inc. | 11 |
| Glaukos Corporation | 10 |
| Bausch & Lomb Incorporated | 9 |
| ForSight Vision5, Inc. | 7 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ocular Hypertension | 483 |
| Glaucoma, Open-Angle | 323 |
| Glaucoma | 237 |
| Eye Diseases | 17 |
| Hypertension | 16 |
| Exfoliation Syndrome | 8 |
| Cataract | 5 |
| Low Tension Glaucoma | 5 |
| Glaucoma, Angle-Closure | 4 |
| Diabetic Retinopathy | 3 |
Trials
Showing 1 to 25 of 483. Each trial links to its page on Pharma Observatory.
383 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.